PharmaVoice 2026-01-15 It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
PharmaVoice 2026-01-14 Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
PharmaVoice 2026-01-08 Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?
PharmaVoice 2025-12-19 Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth